90Y Ibritumomab Tiuxetan
- 27 Downloads
▴ 90Yttrium (90Y) ibritumomab tiuxetan is a radiolabeled murine anti-CD20 monoclonal antibody that binds specifically to the CD20 antigen on normal and malignant B lymphocytes. It has antitumor activity as a result of emission of β particles. It is administered as part of a therapeutic regimen which includes rituximab, a monoclonal antibody which produces antibody-dependent cell-and complement-mediated cytotoxicity.
▴ 90Y ibritumomab tiuxetan, when given as part of the recommended regimen, produced significantly higher overall (80 vs 56%: p = 0.002) and complete response rates (30 vs 16%: p = 0.04) than rituximab alone in a randomized nonblind study in patients with relapsed or refractory low-grade, follicular or transformed non-Hodgkin’s lymphoma (NHL). Quality of life, as measured by the Functional Assessment of Cancer Therapy-General survey, was also improved significantly (from baseline to week 12; p = 0.001) in recipients of ibritumomab tiuxetan but not in rituximab recipients.
▴ In a noncomparative trial in patients with follicular NHL refractory to rituximab, the ibritumomab tiuxetan therapeutic regimen produced overall and complete response rates of 74 and 15%, respectively.The Kaplan-Meier median estimates of the time to progression and duration of response were 6.8 and 6.4 months, respectively.
▴ The dose-limiting toxicity of ibritumomab tiuxetan is reversible myelosuppression which was seen in most patients. Most non-hematological toxicity was mild or moderate.
KeywordsComplete Response Rate Bone Marrow Involvement Nonhematological Toxicity Unlabeled Antibody Ibritumomab Tiuxetan
- 2.Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin’s lymphoma.CurrPharmBiotechnol 2001 Dec; 2(4): 341–9Google Scholar
- 5.Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium- 90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immu-notherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002 May 15; 20(10): 2453–63PubMedCrossRefGoogle Scholar
- 9.IDEC Pharmaceuticals Corporation. Zevalin: product information. San Diego (CA): IDEC Pharmaceuticals Corporation, 2002 JanGoogle Scholar
- 11.Wiseman GA, Gordon LI, Witzig TE, et al. Zevalin radioimmunotherapy is not associated with significant or prolonged depletion of T cells or natural killer cells [abstract]. Blood 2000 Nov 16; 96 (Pt 2): 252Google Scholar
- 13.Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol 2001 Jul; 39: 181–94PubMedCrossRefGoogle Scholar
- 16.Wiseman GA, Leigh BR, Czuczman MS, et al. The pharmacokinetic profile of Zevalin TM is similar when radiolabeled with 90Y from different suppliers [abstract]. Blood 2001 Nov 16; 98 (Pt 2): 254Google Scholar
- 18.IDEC Pharmaceuticals. Product: Zevalin [online]. Available from URL: http://www.idecpharm.com/site/science/zevalin.htm [Accessed 2002 May 13]
- 20.Witzig TE, White CA, Flinn IW, et al. Zevalin (TM) radioimmunotherapy of rituximab-refractory follicular non-Hodgkin’s lymphoma [abstract]. Blood 2000 Nov 16; 96 (Pt 1): 507Google Scholar
- 23.Witzig T, White CA, Wiseman G, et al. IDEC-Y2B8 radioimmunotherapy: responses in patients with splenomegaly [abstract]. Blood 1998 Nov 15; 92 (Pt 1 Suppl. 1): 417Google Scholar
- 26.Emmanoulidies C, Witzig T, Gordon L, et al. Zevalin radioimmunotherapy is safe and effective in geriatric patients with low grade, follicular or CD20+ transformed non-Hodgkin’s lymphoma [plus poster]. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12–15; San Francisco, 286Google Scholar
- 27.Schilder R, Witzig T, Gordon L, et al. Zevalin radioimmunotherapy for low grade, follicular, and Cd20+ transformed non-Hodgkin’s lymphoma is effective even in patients with mild thrombocytopena and poor prognostic factors. 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12–15; San Francisco, 236Google Scholar
- 28.Witzig TE, Gordon L, Gaston I, et al. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy of follicular NHL: results by follicular subtype [abstract]. Proc ASCO 2002; 21: 1063aGoogle Scholar
- 29.Bartlett NL, Witzig TE, Gordon L, et al. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B cell non-Hodgkin’s lymphoma (NHL) patients [abstract]. Proc ASCO 2002; 21: 51aGoogle Scholar
- 30.Gordon LI, Witzig TE, Emmanouilides CE, et al. 90Y ibritumomab (Zevalin) in aggressive non-Hodgkin’s lymphoma: analysis of response and toxicity [abstract]. Proc ASCO 2002 May; 21 (Pt 1): 1061aGoogle Scholar
- 32.Czuczman MS, Emmanouilides CE, Witzig TE, et al. Multivariate analysis of prognostic factors correlated with response to Y90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkins lymphoma [abstract]. Proc ASCO 2002; 21: 1062aGoogle Scholar
- 33.Witzig TE, White CA, Gordon LI, et al. Zevalin TM radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin’s lymphoma [abstract]. Blood 2001 Nov 16; 98 (Pt 1): 606Google Scholar
- 35.Wiseman GA, Leigh BR, Witzig TE, et al. Family members of patients receiving Zevalin TM radioimmunotherapy do not receive radiation exposure above background levels. Blood 2001 Nov 16; 98 (Pt 2): 236–7Google Scholar